肝癌患者经系统治疗后甲胎蛋白变化对预后的影响

摘要

目的:探讨肝癌患者经系统治疗后甲胎蛋白(AFP)变化对患者预后的影响.方法:对53例肝癌患者于入院后和系统治疗后分别于不同时间点测定血清AFP值后,将入院时AFP值作为基线,以变化50％作为标准分组,并进行无疾病进展生存时间(PFS)和总生存时间(OS)分析.结果:9例患者血清AFP值下降超过50％(A组),28例患者AFP值升高超过50％(B组),而AFP值变化小于50％(C组)的为16例.和C组相比,A组患者PFS明显延长(P＜0.05),B组PFS明显缩短(P＜0.05).B组OS短于C组(P＜0.01),而A组和C组间OS无明显差别(P＞0.05).结论:肝癌系统治疗前后的AFP值变化可作为临床上预后判断的标志之一.%Objective: To explore the prognostic influence of the changes of alpha-fetoprotein in patients receiving systemic therapy with hepatocellular carcinoma. Methods: Serum AFP was collected at baseline and at different time points after admission receiving systemic therapy in S3 patients with hepatocellular carcinoma. Patients were separated into different groups based on a 50% change in serum AFP from baseline. Overall survival (OS), progression-free survival (PFS) were compared between groups. Results: Nine patients experienced a >50% AFP decline(Group A), 28 patients had a>50%AFP increase(Group B), and 16 patients had a <50% change in serum AFP in either direction (Group Q.Compared with Group C, Group A had a longer PFS time (P<0.05), whereas Group B had a shorter PFS time (P<0.05). Group B had a shorter OS time than Group C (P<0.01), whereas Group A was not associated with a significant difference in OS (P>0.05). Conclusion: Serum AFP change may serve as a useful marker for clinical outcome and prognostic influence in patients with hepatocellular carcinoma receiving systemic therapy.